

Syntheses of the D-, E-, F-, and I-Ring Parts of Ciguatoxin by a Common Strategy Starting from Tri-*O*-acetyl-D-glucal

Kenshu Fujiwara,^{*a} Yasuhito Koyama,^a Eriko Doi,^a Ken Shimawaki,^a Yuko Ohtaniuchi,^a Atsushi Takemura, Shin-ichiro Souma,^a Akio Murai^{*a,b}

^a Division of Chemistry, Graduate School of Science, Hokkaido University, Sapporo 060-0810, Japan
Fax +81(11)7062714; E-mail: fjwkn@sci.hokudai.ac.jp

^b Present address: 6-14-44 Asabu-cho, Kita-ku, Sapporo 001-0045, Japan
Fax +81(11)7476963; E-mail: amurai@rmail.plala.or.jp

Received 29 May 2002


Abstract: Chiral medium-sized monocyclic ethers corresponding to the D-, E-, F-, and I-ring parts of ciguatoxin have been synthesized from tri-*O*-acetyl-D-glucal through a common synthetic route involving ring-closing olefin metathesis.

Key words: Heterocycles, stereoselective synthesis, natural products, ethers, metathesis

Ciguatoxin (**1**), isolated as one of the causative toxins of ciguatera sea food poisoning, has attracted much attention of synthetic chemists from its unique ladder-shaped polyether structure and strong bioactivity.^{1–4} In the course of our studies toward the total synthesis of **1**,⁵ we planned to construct the D-, E-, F-, and I-ring parts as the key synthetic intermediates. Here, the syntheses of oxepene **2** as the D- or E-ring part, oxonene **3** as the F-ring part, and oxocane **4** as the I-ring part by a common strategy starting from tri-*O*-acetyl-D-glucal (**8**) are described.

Our strategy for the syntheses of **2**, **3**, and **4** is outlined in Scheme 1. Oxepene **2** and oxonene **3** would be constructed readily from diene **5** by a ring-closing olefin metathesis (RCM) reaction.⁶ On the other hand, oxocane **4** should be synthesized through a 2-step process [(i) a RCM reaction between vinyl and propen-2-yl groups of **6** and (ii) the stereoselective reduction of the resultant trisubstituted olefin part]. The dienes **5** and **6** would be provided from C-glycoside **7**, having all requisite stereocenters, through a cleavage at the *cis*-diol part of the hexose ring.⁸ Stereochemistry of **7** would be set up from tri-*O*-acetyl D-glucal (**8**) via diastereoselective introduction of a 1-hydroxy-2-propenyl or 1-hydroxy-3-butenyl side chain.


Syntheses of intermediates **20** and **21** are shown in Scheme 2. Tri-*O*-acetyl-D-glucal (**8**) was converted to **10**⁹ in 52% overall yield through a 3-step process [(i) treatment with TMSCN and SnCl₄,¹⁰ (ii) removal of acetyl groups by methanolysis with Amberlyst 15, and (iii) benzylidene acetal formation]. In the latter two steps, no significant isomerization of a double bond at C3 to a conjugate system was observed. Olefin **10** was oxidized to diol **11** stereoselectively, which was protected with TBS



Scheme 1

to afford **12**. Nitrile **12** was reduced with DIBALH and the resulting imine was hydrolyzed under acidic conditions to produce aldehyde **13**. Stereoselective vinylation of **13** was succeeded with vinyl lithium prepared in situ from vinyl bromide and *t*-BuLi to give **14** in 79% isolated yield (dr 11:1).¹¹ On the other hand, **16** was obtained selectively by allylation of **13** with 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹² in 79% isolated yield (dr 3.8:1).¹¹ These alcohols **14** and **16** were converted to the corresponding cyclic phenyl boronates **20** and **21** in good yields by a 4-step sequence [(i) removal of TBS groups with TBAF; (ii) oxidative cleavage of 1,2-diol parts; (iii) reduction with NaBH₄; (iv) treatment with PhB(OH)₂].¹³


The D/E-ring part **2** was synthesized from **20** as shown in Scheme 3. Firstly, we examined a concise route. Alcohol **20** was converted to diene **24** in only three steps [(i) Swern oxidation, (ii) Wittig olefination, and (iii) removal of cyc-



Scheme 2 Reagents and conditions. a) TMSCN (1.5 equiv), SnCl₄ (1.0 equiv), CH₂Cl₂, -78 °C, 10 min, then -20 °C, 10 min, 61%; b) Amberlyst 15, MeOH, reflux, 24 h; c) PhCHO (3 equiv), Amberlyst 15, CHCl₃, 23 °C, 19 h, then reflux with Dean–Stark trap, 3.5 h, 85% (2 steps); d) OsO₄ (0.01 equiv), NMO (1.4 equiv), 1,4-dioxane–H₂O (3:1), 20 °C, 4 d, ~100%; e) TBSOTf (3 equiv), 2,6-lutidine (6 equiv), CH₂Cl₂, 0 → 22 °C, 72 h, ~100%; f) DIBALH (1 equiv), CH₂Cl₂, -78 °C, 12 min; 1 M HCl aq–CH₂Cl₂ 22 °C, 16 h, 95%; g) CH₂=CHBr (6 equiv), *t*-BuLi (12 equiv), THF, -78 °C, 20 min, then **13**, -78 °C, 1 h, **14**: 79%; h) 2-allyl-4,4,5,5-tetramethyl-1,3-dioxo-2-borolane (6.5 equiv), CH₂Cl₂, -78 °C, 3.5 h, then -20 °C, 20 min, **16**: 79%; i) TBAF (3–3.5 equiv), THF, 22 °C, 25–41 h, **15**: ~100%, **17**: 95%; j) NaIO₄ (1.1–1.3 equiv), 1,4-dioxane–H₂O (3:1), 22 °C, 6–48 h; k) NaBH₄ (2–3.7 equiv), MeOH, 0 °C, 1–2 h, **18**: 99% (2 steps), **19**: 96% (2 steps); l) PhB(OH)₂ (1 equiv), PhH, reflux with Dean–Stark trap, 2.5–4.5 h, **20**: 95%, **21**: 98%

lic boronate part],¹⁴ though the instability of cyclic boronate part caused the low yield (39% overall). Since **24** is not a good precursor for RCM reaction, the primary hydroxy group was protected as pivaloate ester. The resulting **25** was readily cyclized with (Cy₃P)₂Cl₂Ru=CH₂Ph¹⁵ to produce **2**¹⁶ in 80% yield. Next, we also explored an alternative route to **24** in order to avoid the trouble owing to instability of the cyclic boronate group. Protection of alcohol **20** with acetyl group and subsequent removal of cyclic boronate afforded diol **27**, which was protected with TBS group and hydrolyzed to give **29**. Alcohol **29** was converted to diene **24** by Swern oxidation¹⁷ followed by Wittig olefination and desilylation. The D/E-ring part **2** was eventually obtained from **20** in 26% total yield in 5 steps via **23** and in 51% total yield in 9 steps via **31**.


The I- and F-ring parts were synthesized from the corresponding substrates **20** and **21** (Scheme 4). Conversion of hydroxy group in **20** or **21** to chloromethanesulfonate ester¹⁸ followed by a 3-step transformation [(i) removal of cyclic boronate,¹⁴ (ii) protection with TBS, and (iii) substitution with cyanide] gave the corresponding nitrile **38** or **39**. For the F-ring construction, the nitrile group of **39** was reduced with DIBALH to an aldehyde, which was



Scheme 3 Reagents and conditions. a) TPAP (0.06 equiv), NMO (1.5 equiv), MS 4 Å, CH₂Cl₂, 12 min; b) Ph₃PCH₃Br (10 equiv), NaHMDS (10 equiv), THF, 22 °C, 1 h, then **22**, -78 → 22 °C, 9 h, 46% for 2 steps; c) 30% H₂O₂, EtOAc, 20 °C, 1 h, 84%; d) PivCl (1.1 equiv), pyridine, 25 °C, 2.5 h, 80%; e) (Cy₃P)₂Cl₂Ru=CH₂Ph (0.05 equiv), ClCH₂CH₂Cl (5 mM of **25**), reflux, 4 h, 90%; f) AcCl (1.1 equiv), pyridine (2.2 equiv), CH₂Cl₂, 25 °C, 1 h, ~100%; g) 30% H₂O₂, EtOAc, 20 °C, 6 h, 92%; h) TBSOTf (2.6 equiv), 2,6-lutidine (5.2 equiv), CH₂Cl₂, 25 °C, 18 h, ~100%; i) DIBALH (1 equiv), CH₂Cl₂, -78 °C, 8 min, ~100%; j) (COCl)₂ (3 equiv), DMSO (4.8 equiv), CH₂Cl₂, -78 °C, 20 min, then Et₃N (10 equiv), -20 °C, 5 min; k) Ph₃PCH₃Br (2 equiv), NaHMDS (2 equiv), THF, 25 °C, 1 h, then **30**, -78 °C, 6 min, 83% for 2 steps; l) TBAF (2.1 equiv), THF, 25 °C, 2 h, ~100%

subjected to Wittig olefination to produce diene **42**. The diene **42** was transformed into the F-ring part **3**¹⁹ in 98% yield by the RCM reaction with (Cy₃P)₂Cl₂Ru=CH₂Ph.¹⁵ On the other hand, **38** was reduced to aldehyde **40**, which was subjected to addition of MeMgBr followed by oxidation to give ketone **44**. Treatment of **44** with Tebbe reagent²⁰ and the subsequent deprotection and protection process produced dienes **45–47**. After several endeavors using these dienes, we found that the RCM reaction of diene **47** with Grubbs' second generation catalyst **48**²¹ in CH₂Cl₂ (5 mM of **47**) under refluxed conditions afforded cyclized compound **49** in 97% yield.⁷ Stereoselective reduction of **49** was achieved only by homogeneous hydrogenation conditions using Crabtree's catalyst²² to give the I ring part **4**²³ in 88% yield (dr 19:1). Stereochemistry of C5 was confirmed by the existence of NOEs between H5/H3 and between H5/H7 in NOESY of **4**. It is noted that this step showed unusual face selectivity which did not result from the coordination of the catalyst with the allylic hydroxy group of **49**.^{22b} Interestingly, hydrogenation of **49** under heterogeneous conditions using PtO₂ gave the opposite selectivity (50% yield, dr 1:8).

Thus, chiral medium-sized monocyclic ethers corresponding to the D-, E-, F-, and I-ring parts of ciguatoxin have been synthesized from tri-*O*-acetyl-D-glucal through a common synthetic route involving ring-closing olefin metathesis. Further studies toward the total synthesis of **1** are currently under way in this laboratory.



Scheme 4 Reagents and conditions. a) $\text{ClCH}_2\text{SO}_2\text{Cl}$ (1–1.5 equiv), 2,6-lutidine (2–3 equiv), CH_2Cl_2 , 21–23 °C, 2–2.5 h, **32**: ~100%, **33**: 98%; b) 30% H_2O_2 , EtOAc, 21–23 °C, 2 h; c) TBSOTf (3–4.3 equiv), 2,6-lutidine (6–10 equiv), CH_2Cl_2 , 21–25 °C, 2–7 h, **35**: 97% from **32**, **37**: 88% from **33**; d) KCN (6 equiv), DMSO, 23–25 °C, 12–15 h, **38**: 95%, **39**: 96%; e) DIBALH (1 equiv), CH_2Cl_2 , –78 °C, 30–40 min, **40**: 97%, **41**: 88%; f) $\text{Ph}_3\text{PCH}_2\text{Br}$ (5 equiv), NaHMDS (4.8 equiv), THF, 22 °C, 2 h, then **41**, –78 °C $\rightarrow$ 23 °C, 4 h, 99%; g) $(\text{Cy}_3\text{P})_2\text{Cl}_2\text{Ru}=\text{CH}_2\text{Ph}$ (0.16 equiv), CH_2Cl_2 (3 mM of **42**), reflux, 3 h, 98%; h) MeMgBr (2 equiv), Et_2O , 0 °C, 1.5 h, 89%; i) DMPI (2 equiv), NaHCO_3 (2 equiv), CH_2Cl_2 , 0 $\rightarrow$ 23 °C, 1 h, ~100%; j) Tebbe reagent (5 equiv), THF, 0 °C, 5 min, 88%; k) TBAF (3.5 equiv), THF, 23 °C, 14 h, ~100%; l) TBDPSCl (2 equiv), imidazole (6 equiv), DMF, 23 °C, 17 h, 77%; m) **48** (0.1 equiv), CH_2Cl_2 (5 mM of **47**), reflux, 4 h, 97%; n) H_2 , [(cod)(py)(Cy₃P)Ir]PF₆ (0.3 equiv), CH_2Cl_2 , –20 °C, 4.5 h, 88% (dr 19:1)

Acknowledgement

The authors are grateful to Mr. Kenji Watanabe and Dr. Eri Fukushima (GC-MS & NMR Laboratory, Graduate School of Agriculture, Hokkaido University) for the measurements of mass spectra.

References

- For isolation and structure determination of ciguatoxin, see: (a) Scheuer, P. J.; Takahashi, W.; Tsutsumi, J.; Yoshida, T. *Science* **1967**, 155, 1267. (b) Tachibana, K. *Ph.D. Thesis*; University of Hawaii: Hawaii, **1980**. (c) Nukina, M.; Koyanagi, L. M.; Scheuer, P. J. *Toxicon* **1984**, 22, 169. (d) Murata, M.; Legrand, A.-M.; Ishibashi, Y.; Fukui, M.; Yasumoto, T. *J. Am. Chem. Soc.* **1989**, 111, 8929. (e) Murata, M.; Legrand, A.-M.; Ishibashi, Y.; Fukui, M.; Yasumoto, T. *J. Am. Chem. Soc.* **1990**, 112, 4380. (f) Satake, M.; Morohashi, A.; Oguri, H.; Oishi, T.; Hiram, M.; Harada, N.; Yasumoto, T. *J. Am. Chem. Soc.* **1997**, 119, 11325. (g) For reviews on ciguatoxin and related marine toxins, see: Yasumoto, T.; Murata, M. *Chem. Rev.* **1993**, 93, 1897. (h) See also: Scheuer, P. J. *Tetrahedron* **1994**, 50, 3. (i) For a review on ciguatera, see: Lewis, R. L. *Toxicon* **2001**, 39, 97.
- For the bioactivities of ciguatoxin and related compounds, see: (a) Bidard, J.-N.; Vijverberg, H. P. M.; Frelin, C.; Chungue, E.; Legrand, A.-M.; Bagnis, R.; Lazdanski, M. *J. Biol. Chem.* **1984**, 259, 8353. (b) Lombet, A.; Bidard, J. N.; Lazdanski, M. *FEBS Lett.* **1987**, 219, 355. (c) For a review, see: Dechraoui, M.-Y.; Naar, J.; Pauillac, S.; Legrand, A.-M. *Toxicon* **1999**, 37, 125; see also the references cited in ref. 1i.
- For the total synthesis of CTX3C, a congener of ciguatoxin, see: Hiram, M.; Oishi, T.; Uehara, H.; Inoue, M.; Maruyama, M.; Oguri, H.; Satake, M. *Science* **2001**, 294, 1904.
- For recent synthetic studies on ciguatoxins, see: (a) Sasaki, M.; Noguchi, T.; Tachibana, K. *J. Org. Chem.* **2002**, 67, 3301. (b) Takai, S.; Isobe, M. *Org. Lett.* **2002**, 4, 1183. (c) Bond, S.; Perlmutter, P. *Tetrahedron* **2002**, 58, 1779. (d) Maruyama, M.; Inoue, M.; Oishi, T.; Oguri, H.; Ogasawara, Y.; Shindo, Y.; Hiram, M. *Tetrahedron* **2002**, 58, 1835. (e) Kira, K.; Hamajima, A.; Isobe, M. *Tetrahedron* **2002**, 58, 1875. (f) Sasaki, M.; Ishikawa, M.; Fuwa, H.; Tachibana, K. *Tetrahedron* **2002**, 58, 1889. (g) Canden, M. L.; Pinto, F. M.; Cintado, C. G.; Morales, E. Q.; Brouard, I.; Díaz, M. T.; Rico, M.; Rodríguez, E.; Rodríguez, R. M.; Pérez, R.; Pérez, R. L.; Martín, J. D. *Tetrahedron* **2002**, 58, 1921. (h) Takakura, H.; Noguchi, K.; Sasaki, M.; Tachibana, K. *Angew. Chem. Int. Ed.* **2001**, 40, 1090. (i) Oishi, T.; Tanaka, S.-I.; Ogasawara, Y.; Maeda, K.; Oguri, H.; Hiram, M. *Synlett* **2001**, 952. (j) Imai, H.; Uehara, H.; Inoue, M.; Oguri, H.; Oishi, T.; Hiram, M. *Tetrahedron Lett.* **2001**, 42, 6219. (k) Saeeng, R.; Isobe, M. *Heterocycles* **2001**, 54, 789. (l) Oguri, H.; Tanaka, S.; Oishi, T.; Hiram, M. *Tetrahedron Lett.* **2000**, 41, 975. (m) Sasaki, M.; Noguchi, K.; Fuwa, H.; Tachibana, K. *Tetrahedron Lett.* **2000**, 41, 1425. (n) Kira, K.; Isobe, M. *Tetrahedron Lett.* **2000**, 41, 5951. (o) Liu, T.-Z.; Isobe, M. *Tetrahedron* **2000**, 56, 5391. (p) Liu, T.-Z.; Isobe, M. *Tetrahedron* **2000**, 56, 10209. (q) Hosokawa, S.; Isobe, M. *J. Org. Chem.* **1999**, 64, 37. (r) Leeuwenburgh, M. A.; Kulker, C.; Overkleeft, H. S.; van der Marel, G. A.; van Boom, J. H. *Synlett* **1999**, 1945. (s) Oishi, T.; Nagumo, Y.; Shoji, M.; Le Brazidec, J.-Y.; Uehara, H.; Hiram, M. *Chem. Commun.* **1999**, 2035. (t) Oishi, T.; Maruyama, M.; Shoji, M.; Maeda, K.; Kumahara, N.; Tanaka, S.; Hiram, M. *Tetrahedron* **1999**, 55, 7471. (u) Oguri, H.; Sasaki, S.; Oishi, T.; Hiram, M. *Tetrahedron Lett.* **1999**, 40, 5405. (v) Eriksson, L.; Guy, S.; Perlmutter, P.; Lewis, R. *J. Org. Chem.* **1999**, 64, 8396. (w) Sasaki, M.; Inoue, M.; Takamatsu, K.; Tachibana, K. *J. Org. Chem.* **1999**, 64, 9399. (x) Inoue, M.; Sasaki, M.; Tachibana, K. *J. Org. Chem.* **1999**, 64, 9416. (y) Inoue, M.; Sasaki, M.; Tachibana, K. *Tetrahedron* **1999**, 55, 10949.

- (5) For synthetic studies on ciguatoxin in this laboratory, see: (a) Oka, T.; Murai, A. *Chem. Lett.* **1994**, 1611. (b) Oka, T.; Fujiwara, K.; Murai, A. *Tetrahedron* **1996**, 52, 12091. (c) Atsuta, H.; Fujiwara, K.; Murai, A. *Synlett* **1997**, 307. (d) Oka, T.; Fujiwara, K.; Murai, A. *Tetrahedron Lett.* **1997**, 38, 8053. (e) Oka, T.; Murai, A. *Tetrahedron* **1998**, 54, 1. (f) Oka, T.; Fujiwara, K.; Murai, A. *Tetrahedron* **1998**, 54, 21. (g) Fujiwara, K.; Saka, K.; Takaoka, D.; Murai, A. *Synlett* **1999**, 1037. (h) Fujiwara, K.; Tanaka, H.; Murai, A. *Chem. Lett.* **2000**, 610. (i) Fujiwara, K.; Takaoka, D.; Kusumi, K.; Kawai, K.; Murai, A. *Synlett* **2001**, 691.
- (6) For recent reviews on olefin metathesis, see: (a) Grubbs, R. H.; Miller, S. J.; Fu, G. C. *Acc. Chem. Res.* **1995**, 28, 446. (b) Schuster, M.; Blechert, S. *Angew. Chem., Int. Ed. Engl.* **1997**, 36, 2067. (c) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, 54, 4413. (d) Armstrong, S. K. *J. Chem. Soc., Perkin Trans. 1* **1998**, 371. (e) Blechert, S. *Pure Appl. Chem.* **1999**, 71, 1393. (f) Fürstner, A. *Angew. Chem. Int. Ed.* **2000**, 39, 3013.
- (7) For the construction of an 8-membered cyclic trisubstituted alkene by the RCM reaction using Grubbs' second generation catalyst **48**,²¹ see: (a) Fürstner, A.; Thiel, O. R.; Ackermann, L.; Schanz, H.-J.; Nolan, S. P. *J. Org. Chem.* **2000**, 65, 2204. (b) See also: Fürstner, A.; Thiel, O. R.; Ackermann, L. *Org. Lett.* **2001**, 3, 449.
- (8) The similar ring cleavage of a C-glycoside for the preparation of a RCM precursor having a chiral dialkyl ether part has been applied for the total synthesis of prelaureatin in this laboratory: Fujiwara, K.S.; Souma, S.; Mishima, H.; Murai, A. *Synlett* **2002**, 1493.
- (9) Tulshian, D. B.; Fraser-Reid, B. *J. Org. Chem.* **1984**, 49, 518.
- (10) Cyanation of **8** was performed by the modified method of the following report: De Las Heras, F. G.; San Felix, A.; Fernández-Resa, P. *Tetrahedron* **1983**, 39, 1617.
- (11) Stereochemistry of the allylic hydroxy group in **14** or the homoallylic one in **16** was confirmed by ¹H NMR using modified Mosher's method. See: Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, 113, 4092.
- (12) Hoffmann, R. W.; Endesfelder, A.; Zeiß, H.-J. *Carbohydr. Res.* **1983**, 123, 320.
- (13) Ferrier, R. J. *Methods Carbohydr. Chem.* **1972**, 6, 419.
- (14) Evans, D. A.; Polniaszek, R. P. *Tetrahedron Lett.* **1986**, 27, 5683.
- (15) Fu, G. C.; Nguyen, S. T.; Grubbs, R. H. *J. Am. Chem. Soc.* **1993**, 115, 9856.
- (16) Representative data for **2**: a colorless oil; [α]_D²² +23.3 (c, 0.06, CHCl₃); ¹H NMR (300 MHz, CDCl₃), δ 7.48 (2 H, m, Ph), 7.36 (3 H, m, Ph), 5.77 (2 H, m, H4, H5), 5.30 (1 H, s, acetal), 4.53 (1 H, dd, *J* = 12, 4.3 Hz, H8a), 4.31–4.17 (4 H, m, H1eq, H3, H6, H8b), 3.64 (1 H, t, *J* = 10 Hz, H1ax), 3.60–3.56 (1 H, m, H7), 3.52 (1 H, dt, *J* = 10, 4.8 Hz, H2), 2.92 (1 H, d, *J* = 5.7 Hz, 6-OH), 1.24 (9 H, s, *t*-Bu); IR (film): 3487, 2971, 2860, 1729, 1481, 1456, 1399, 1287, 1167, 1115, 1032, 977, 752, 698 cm⁻¹; HR-EIMS, calcd for C₂₀H₂₆O₆ (M)⁺: 362.1729, found: 362.1722.
- (17) (a) Omura, K.; Swern, D. *Tetrahedron* **1978**, 34, 1651. (b) Mancuso, A. J.; Huang, S.-L.; Swern, D. *J. Org. Chem.* **1978**, 43, 2480. (c) Mancuso, A. J.; Swern, D. *Synthesis* **1981**, 165.
- (18) (a) Shimizu, T.; Hiranuma, S.; Nakata, T. *Tetrahedron Lett.* **1996**, 37, 6145. (b) Shimizu, T.; Ohzeki, T.; Hiramoto, K.; Hori, N.; Nakata, T. *Synthesis* **1999**, 1373.
- (19) Representative data for **3**: a colorless oil; [α]_D²¹ –9.2 (c 0.29, CHCl₃); ¹H NMR (400 MHz, CDCl₃, 55 °C), δ 7.28–7.48 (5 H, m, Ph), 5.74–5.82 (2 H, m, H5, H6), 5.40 (1 H, s, acetal), 4.52 (1 H, dd, *J* = 4.3, 10.3 Hz, H1eq), 3.77 (1 H, dd, *J* = 1.8, 10.6 Hz, H10a), 3.62–3.70 (2 H, m, H3, H8), 3.57 (1 H, dt, *J* = 4.3, 10.3 Hz, H2), 3.50 (1 H, t, *J* = 10.3 Hz, H1ax), 3.44 (1 H, dd, *J* = 7.7, 10.6 Hz, H10b), 3.32 (1 H, dt, *J* = 1.8, 7.7 Hz, H9), 2.68–2.80 (1 H, m, H4a), 2.44–2.58 (2 H, m, H7a, H4b), 2.28–2.43 (1 H, m, H7b), 0.91 (9 H, s, TBS), 0.90 (9 H, s, TBS), 0.098 (3 H, s, TBS), 0.070 (3 H, s, TBS), 0.066 (3 H, s, TBS), 0.049 (3 H, s, TBS); IR(film): 2955, 2928, 2856, 1471, 1462, 1389, 1361, 1294, 1258, 1213, 1148, 1103, 1027, 977, 836, 811, 776, 747, 665 cm⁻¹; HR-FDMS, calcd for C₂₉H₅₁O₅Si₂ (M + H)⁺: 535.3298, found: 535.3275.
- (20) (a) Tebbe, F. N.; Parshall, G. W.; Reddy, G. S. *J. Am. Chem. Soc.* **1978**, 100, 3611. (b) Tebbe, F. N.; Parshall, G. W.; Reddy, G. S. *J. Am. Chem. Soc.* **1979**, 101, 5074. (c) Pine, S. H.; Zahler, R.; Evans, D. A.; Grubbs, R. H. *J. Am. Chem. Soc.* **1980**, 102, 3270. (d) Pine, S. H.; Kim, G.; Lee, V. *Org. Synth.* **1990**, 69, 72.
- (21) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. *Org. Lett.* **1999**, 1, 953.
- (22) (a) Crabtree, R. H.; Felkin, H.; Morris, G. E. *J. Chem. Soc., Chem. Commun.* **1976**, 716. (b) Crabtree, R. H.; Felkin, H.; Fellebeen-Khan, T.; Morris, G. E. *J. Organometal. Chem.* **1979**, 168, 183. (c) Crabtree, R. H.; Davis, M. W. *Organometallics* **1983**, 2, 681. (d) Stork, G.; Kahne, D. E. *J. Am. Chem. Soc.* **1983**, 105, 1072.
- (23) Representative data for **4**: a colorless oil; [α]_D²⁵ +13.3 (c 0.15, CHCl₃); ¹H NMR [400 MHz, C₆D₆–CDCl₃ (1:1)], δ 7.66–7.72 (4 H, m, Ph), 7.51–7.47 (2 H, m, Ph), 7.33–7.15 (9 H, m, Ph), 5.29 (1 H, s, acetal), 4.08–4.17 (1 H, m, H1eq), 3.75 (1 H, dd, *J* = 10.5, 5.4 Hz, H9a), 3.69 (1 H, dd, *J* = 10.5, 5.9 Hz, H9b), 3.50–3.59 (1 H, m, H7), 3.42–3.50 (1 H, m, H3), 3.35–3.41 (2 H, m, H1ax, H2), 3.26 (1 H, brdt, *J* = 8.9, 5.5 Hz, H8), 2.28 (1 H, m, 7-OH), 1.91 (1 H, brdd, *J* = 13.8, 3.5 Hz, H4a), 1.62–1.64 (1 H, m, H5), 1.53–1.62 (3 H, m, H4b, H6), 1.09 (9 H, s, *t*-Bu), 1.00 (3 H, d, *J* = 7.1 Hz, 5-Me); IR(film): 3490, 3071, 3047, 2928, 2857, 1589, 1455, 1428, 1391, 1372, 1292, 1215, 1112, 1029, 916, 823, 744, 701, 615 cm⁻¹; HR-EIMS, calcd for C₂₉H₃₃O₅Si (M – *t*-Bu)⁺: 489.2097, found: 489.2105.